Oral division
Orforglipron (Foundayo)
BCompetitive
Eli Lilly · approved
vs
Injectable division
Semaglutide 2.4 mg (Wegovy)
CompetitiveB
Novo Nordisk · approved
9%
Efficacy
3 pts more · 12%
Notable (+7.6)
Tolerability
gentler · Mild (+3.9)
Oral pill
Route
Subcutaneous injection
None
Food / water rule
None
Room temperature
Storage
Refrigerated (room temperature up to 28 days)
The trade: A pill against the original injection. Semaglutide loses more weight; orforglipron gives that back as a daily tablet with no needle, no fasting rule, and no cold chain. Different divisions, so this is the trade, not a verdict: if maximum loss matters most, the injection; if a pill you will actually stay on matters more, orforglipron.
Standalone, this page carries its own key: Efficacy = % body weight lost vs placebo, on the conservative estimand that counts everyone. Tolerability = AE-discontinuation over placebo (Mild 1 to 5 · Notable 5 to 10 · Heavy over 10 points). Different divisions, so efficacy is shown as raw magnitude, not a verdict. The side marked leads or gentler wins that axis.
Orforglipron verdict · Semaglutide 2.4 mg verdict · Is the pill as good as the shot? · How this is scored